Skip to content

Controlled Versus Standard Oxygen Therapy in ICU Patients With Acute Exacerbation of COPD

Effect of a Controlled Versus Standard Oxygen Therapy Strategy in ICU Patients With Acute Exacerbation of COPD: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07842510
Acronym
OXYCOPD-ICU
Enrollment
240
Registered
2026-09-25
Start date
2026-01-01
Completion date
2028-12-31
Last updated
2026-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD), Acute Exacerbation of COPD, Intensive Care Unit (ICU), Controlled Oxygen Therapy, Mechanical Ventilation Complication

Keywords

COPD; Acute exacerbation; Controlled oxygen therapy; Mechanical ventilation; Intensive care unit.

Brief summary

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Acute exacerbations frequently require intensive care unit (ICU) admission. Oxygen therapy is an essential component of treatment; however, excessive oxygen administration may aggravate hypercapnia and respiratory acidosis. Current international guidelines recommend titrated oxygen therapy targeting an oxygen saturation of 88-92% in patients with acute exacerbation of COPD, but evidence supporting this strategy in critically ill ICU patients remains limited. This randomized controlled trial aims to compare a controlled oxygen therapy strategy (target oxygen saturation 88-92%) with standard oxygen therapy (oxygen saturation \>94%) in ICU patients admitted with acute exacerbation of COPD. The primary objective is to determine whether controlled oxygen therapy reduces the duration of mechanical ventilation (invasive and non-invasive). Secondary objectives include assessing the 28-day mortality, ICU length of stay, the need for invasive mechanical ventilation, and adverse events related to hyperoxia.

Interventions

OTHERControlled oxygen therapy

Oxygen therapy will be administered using an adjustable oxygen delivery device, including nasal cannula, Venturi mask, or high-flow nasal oxygen, and titrated to maintain peripheral oxygen saturation (SpO₂) between 88% and 92%.

Oxygen therapy will be administered according to the usual practice of the intensive care unit and adjusted to maintain peripheral oxygen saturation (SpO₂) above 94%.

Sponsors

Hôpital Universitaire Taher Sfar
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 40 years * Established diagnosis of chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria * Admission to the intensive care unit for an acute exacerbation of COPD, with or without respiratory acidosis * Written informed consent provided by the participant or their legally authorized representative

Exclusion criteria

* Endotracheal intubation performed before enrollment * Severe decompensated heart failure with a left ventricular ejection fraction \< 30% * Active terminal malignancy * Refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Total duration of mechanical ventilationFrom randomization until definitive discontinuation of mechanical ventilation Up to 28 days after randomizationTotal cumulative duration of mechanical ventilation, defined as the sum of the duration of non-invasive ventilation and invasive mechanical ventilation.

Secondary

MeasureTime frame
Mortality at Day 28Day 28 after randomization
Length of stay in the intensive care unitFrom randomization until ICU discharge or death, up to 28 days
Requirement for invasive mechanical ventilationFrom randomization until ICU discharge or death

Countries

Tunisia

Contacts

CONTACTHajer Nouira
nouirahajer@gmail.com+21622858699

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 26, 2026